These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17867592)

  • 21. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
    Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
    Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
    Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
    Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
    Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
    Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract].
    Burger M; Catto J; van Oers J; Zwarthoff E; Hamdy FC; Meuth M; Azzouri AR; Cussenot O; Wild PJ; Stoehr R; Hartmann A
    Verh Dtsch Ges Pathol; 2006; 90():244-52. PubMed ID: 17867603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
    Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
    J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
    Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
    Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
    Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
    Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
    Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development.
    Zieger K; Marcussen N; Borre M; Ørntoft TF; Dyrskjøt L
    Int J Cancer; 2009 Nov; 125(9):2095-103. PubMed ID: 19637316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
    Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
    Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma.
    Bakkar AA; Allory Y; Iwatsubo Y; de Medina SG; Maille P; Khreich N; Riou A; Leroy K; Vordos D; Abbou CC; Andujar P; Billebaud T; Chammings S; Conso F; De La Taille A; Fontaine E; Gattegno B; Ravery V; Sibony M; Radvanyi F; Chopin DK; Pairon JC
    Mol Carcinog; 2010 Jan; 49(1):25-31. PubMed ID: 19722178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bladder cancer: novel molecular characteristics, diagnostic, and therapeutic implications.
    Kompier LC; van Tilborg AA; Zwarthoff EC
    Urol Oncol; 2010; 28(1):91-6. PubMed ID: 20123356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Preliminary study of p53 and FGFR3 gene mutations in the urine for bladder tumors].
    Noël N; Couteau J; Maillet G; Gobet F; d'Aloisio F; Minier C; Pfister C
    Prog Urol; 2013 Jan; 23(1):29-35. PubMed ID: 23287481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 and FGFR3 Gene Mutation Assessment in Urine: Pilot Study for Bladder Cancer Diagnosis.
    Noel N; Couteau J; Maillet G; Gobet F; D'Aloisio F; Minier C; Pfister C
    Anticancer Res; 2015 Sep; 35(9):4915-21. PubMed ID: 26254388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer.
    Pandith AA; Shah ZA; Siddiqi MA
    Urol Oncol; 2013 May; 31(4):398-406. PubMed ID: 20822928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.